I'm less optimistic and think this is a red herring, I mean big pharma acquire clinical phase 2 success drugs every day of the week, why is this one awaiting FDA approval based on merely updated instructions still deemed insufficiently attractive? Clearly I'm missing something.
I'm less optimistic and think this is a red herring, I mean big...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.005(1.79%) |
Mkt cap ! $433.1M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.5¢ | 27.5¢ | $954.6K | 3.406M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 641411 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 249809 | 2 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
28.0¢ |
Change
-0.005 ( 1.78 %) |
||||
| Open | High | Low | Volume | ||
| 28.0¢ | 29.0¢ | 27.5¢ | 1489291 | ||
| Last updated 15.59pm 07/06/2024 ? | |||||
| BOT (ASX) Chart |